MERCK AND PFIZER JOIN FORCES ON A DIABETES DRUG
Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP
Pharmaceutical companies, Merck & Co Inc and Pfizer Inc have announced that they will be co-developing Pfizer's experimental type 2 diabetes drug, ertugliflozin. This drug will be marketed as a standalone product and in combination with metformin, and other drugs including --Januvia/Janumet--both of which are subject to litigation for pancreatitis and pancreatic cancer. Merck and Pfizer will split revenue and certain costs on a 60-40 percent basis. With their new collaboration, the drug makers are hoping to reestablish the trust diabetes patients lost in Merck with Januvia/Janumet and develop a new type of treatment that can avoid the sort of side effects that Januvia had. Last year, the widely used diabetes treatment generated approximately $4 billion in sales; however, the safety of the medication has been under increased scrutiny in recent weeks. The FDA is currently investigating these incretin mimetic drugs used to stimulate insulin production in diabetic patients, as they may be associated with an increased risk of developing pancreatic cancer. Despite receiving a warning letter from the FDA to conduct post-market studies for Januvia/Janumet, Merck failed to meet the deadlines and put thousands of patients at risk of pancreatic problems.
If you or a loved one is a diabetic patient who developed pancreatic cancer after taking Januvia, Janumet, Byetta or Victoza, please contact us today to speak with an experienced New York drug product liability law firm. You have significant legal rights, and may be entitled to compensation against drug manufacturers for their negligence.